Information Provided By: 
Fly News Breaks for November 14, 2016
PBYI
Nov 14, 2016 | 12:24 EDT
RBC Capital analyst Simo Simeonidis said today's release of worsening diarrhea in trial patients on Puma Biotechnology's neratinib, compared to last year's data, helps explain the need for a change in the trial design. While the 12.5% rate of G3 diarrhea is potentially promising, the small sample size and fact that these data are still early, and the fact that loperamide alone no longer appears sufficient to prophylaxe against severe diarrhea, are significant negatives, said Simeonidis, who has a Sector Perform rating on Puma shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
